End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
21.78 CNY | -1.80% | -4.39% | -21.65% |
Apr. 25 | Hualan Biological Vaccine Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 01 | Hualan Biological Vaccine Inc. Proposes Final Cash Dividend for 2023 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-21.65% | 1.84B | - | ||
-1.26% | 89.46B | A- | ||
+2.76% | 40.74B | A- | ||
-9.06% | 33.03B | B- | ||
+55.32% | 24.68B | A | ||
-16.61% | 15.12B | C | ||
-9.14% | 12.81B | B- | ||
-12.11% | 11.79B | D+ | ||
-43.61% | 11.64B | B | ||
+7.79% | 8.9B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 301207 Stock
- Ratings Hualan Biological Vaccine Inc.